26 May 2016 
EMA/CHMP/207100/2016 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Adcetris 
brentuximab vedotin 
On 26 May 2016, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Adcetris. 
The marketing authorisation holder for this medicinal product is Takeda Pharma A/S. 
The CHMP adopted a new indication as follows: 
"Adcetris is indicated for the treatment of adult patients with CD30+ HL at increased risk of 
relapse or progression following ASCT (see section 5.1)". 
For information, the full indications for Adcetris will be as follows2: 
“Adcetris is indicated for the treatment of adult patients with relapsed or refractory CD30+ 
Hodgkin lymphoma (HL):  
1. 
2. 
following autologous stem cell transplant (ASCT) or 
following at least two prior therapies when ASCT or multi-agent chemotherapy is not a 
treatment option. 
Adcetris is indicated for the treatment of adult patients with CD30+ HL at increased risk 
of relapse or progression following ASCT (see section 5.1). 
Adcetris is indicated for the treatment of adult patients with relapsed or refractory systemic 
anaplastic large cell lymphoma (sALCL).” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 
 
 
  
 
 
 
  
                                                
